Serum klotho: a potential predictor of cerebrovascular disease in hemodialysis patients

Honglan Wei†, Hua Li†, Xiaohong Song, Xingguo Du, Yuan Cai, Chengxu Li, Liping Dong and Junwu Dong*

Abstract

Background: Hemodialysis patients suffer from a serious threat of cerebrovascular disease. Klotho, as an aging-suppressor gene, contributes to protect on vascular calcification and oxidative stress, which are the risk factors of cerebrovascular disease. The purpose of the present study is to determine the relationship between serum klotho and cerebrovascular disease in patients receiving hemodialysis.

Methods: Serum klotho levels of hemodialysis patients were measured by ELISA. Cerebrovascular diseases were diagnosed by CT or MRI scans. The cognitive function of hemodialysis patients with cerebrovascular disease were evaluated with a neuropsychological battery assessing domains of global cognition verbal memory, spatial memory, executive function and verbal fluency.

Results: Eighty-eight patients were included, 57 ± 14 years, 63.64% male, 52.27% older than 60 years. Twenty-eight participants had cerebrovascular disease (23 cases had cerebral infarction, 5 cases had cerebral hemorrhage). The average level of serum klotho of all participants was 119.10 ± 47.29 pg/ml. The serum klotho level was significantly associated with cerebrovascular disease in hemodialysis patients (HR(95%CI) = 0.975(0.960–0.990), p = 0.001). The optimal cut-off value of serum klotho for predicting cerebrovascular disease in hemodialysis patients was 137.22 pg/ml, with a specificity of 96.4% and a sensitivity of 46.7%. But serum klotho was not an independent risk factor of cognitive impairment for hemodialysis patients with cerebrovascular disease (HR((95%CI) = 1.002(0.986–1.018), p = 0.776) or with cerebral infarction (HR(95%CI) = 1.005(0.987–1.023), p = 0.576).

Conclusions: The serum klotho level is a potential predictor of cerebrovascular disease in hemodialysis patients, but it is not an independent risk factor of cognitive impairment for hemodialysis patients with cerebrovascular disease.

Keywords: Hemodialysis, Klotho, Cerebrovascular disease, Cognitive impairment

Background

Over the past decade, chronic kidney disease (CKD), defined as a decreased glomerular filtration rate or increased albuminuria is recognized as a worldwide important public health problem, which is highly prevalent in developing countries. China is the largest developing country. In Chinese adults, the prevalence of CKD is 10.8% [1]. It means that there are about 119.5 million Chinese aged 18 years or older have CKD [1]. With the prevalence of CKD, end-stage renal disease (ESRD) has become an emerging worldwide health burden because of its many complications, high costs and mortality risk. Renal replacement therapy, containing hemodialysis, peritoneal dialysis and kidney transplant, is the main treatment for end-stage renal disease currently. There are about 2.2 million end-stage renal disease patients receiving renal replacement therapy, and hemodialysis accounts for 89%. In China, 454,000 patients are receiving hemodialysis in 2016, where the number is 276,008 in 2011.

Hemodialysis is associated with raised risk of cardiovascular disease (CVD), infection, cerebrovascular...
Cerebrovascular disease is prevalent in hemodialysis patients with cerebrovascular disease experience short-term mortality [4]. Except that, disability and cognitive impairment are very common in survivors [5, 6]. Cerebrovascular disease is prevalent in hemodialysis patients partly related to the traditional risk factors, such as age, hypertension, diabetes mellitus and dyslipidemia.

Based on the strong vascular-protective effects of klotho, the current study aimed to confirm the relationship between serum klotho and cerebrovascular disease in hemodialysis patients. It is hypothesized that decreased serum klotho protein is the novel risk factor for cerebrovascular disease in hemodialysis patients.

Methods
Participants
From November 2014 to March 2015, we recruited participants from the Dialysis Center in Puai hospital of Tongji medical college, Huazhong University. Eligible participants were 18 years or older, receiving maintenance hemodialysis for at least 3 months, and had undergone head CT or MRI examination in the past 1 year which excluded the history of stroke or silent brain infarction (SBI). Cerebral hemorrhage caused by craniocebral trauma during the study and patients with stroke history were excluded. Patients were also excluded if they had an active psychiatric disorder, Alzheimer’s disease, or if they had significant visual or hearing impairment. Serum klotho measurement and other laboratory studies were carried out at the beginning of the study. Every participant was followed up for 24 months. If the participants have stroke symptoms, head CT or MRI were scanned immediately. The others without stroke symptoms during the following time, head MRI were carried out in the last month of the study.

Cerebrovascular disease
Cerebrovascular diseases, including clinical stroke and SBI, were diagnosed by two neurology specialists and two imaging specialists. Clinical stroke were diagnosed through head CT or MRI scans and clinical symptoms which contain sudden onset of unilateral numbness, unilateral weakness, loss of ability to communicate, loss of ability to understand, loss of vision, and loss of half the visual field. SBI was diagnosed through MRI.

Laboratory studies
The fasting blood samples were collected in the morning and pre-dialysis. After collection, the blood samples were centrifuged immediately, serum and plasma were obtained and stored at -80 °C. Serum klotho was detected by ELISA [14, 15], and antibodies were purchased from Xinfan Bio technology company, Shanghai, China. Automatic biochemical analyzer (Mindray, Shenzhen, China) was used for measuring albumin (ALB), calcium (Ca), phosphate (P), iron, total iron binding capacity (TIBC), total cholesterol (Tch), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) concentrations and Low-density lipoprotein cholesterol (LDL-C). Hemoglobin (Hb) was measured by Automatic blood analyzer (Mindray, Shenzhen, China). Serum ferritin (SF) and parathyroid hormone (PTH) was measured by Radioimmunoassay (Beckman Coulter, California, USA).

Cognitive function
All the patients with cerebrovascular disease were evaluated cognitive function with a neuropsychological battery assessing domains of global cognition verbal memory, spatial memory, executive function and verbal fluency. Global cognition was assessed with the mini-mental state examination (MMSE). Verbal memory was assessed with the Hopkins Verbal Learning Test-Revised (HVLT-R) immediate and delayed recall components [16]. Spatial memory was assessed with the Brief Visuospatial Memory Test-Revised (BVMT-R) [17]. Executive function was assessed with the Trail A test [18]. Verbal fluency was assessed with the Verbal Fluency Test (VFT) [19]. Cognitive impairment was defined as a score at least 1.5 SD below normative values for age in 2 or more cognitive domains [20].

Statistical analysis
Datos with non-normal distribution were expressed as medians and interquartile ranges (25th and 75th percentiles) or percentages for categorical variables, while others with normal distribution were expressed as mean ± SD. We compared characteristics of patients with cerebrovascular disease to those without using the 2-tailed Student’s t-test. Categorical data are presented as numbers and percentages and compared using the Chi-square test.

Cox regression analysis was used to explore the independent risk factors of cerebrovascular disease in hemodialysis patients. A receiver operating characteristic
(ROC) curve was performed to examine the prognostic utility of serum klotho and to identify the optimal cut-off value.

The relationship between klotho and cognitive function of patients with cerebrovascular disease was explored using Cox regression models: model 1, crude model; model 2, additionally adjusting for age; model 3, additionally adjusting for diabetes mellitus (DM).

The correlations between the different parameters and klotho levels were evaluated using a correlation test.

All statistical analyses were performed using SPSS (version 20, IBM Corp, Amonk, NY, USA). A p-value < 0.05 was considered statistically significant.

**Results**

**Participants’ characteristics**

A total of 185 patients were screened. The hemodialysis patients with stroke history (n = 20) or without head CT or MRI in the past 1 year to certify who had no stroke or silent brain infarction were excluded (n = 15). Patients were also excluded if they had an active psychiatric disorder (n = 2), Alzheimer’s disease (n = 18), or if they had significant visual or hearing impairment (n = 24). Eighteen patients refused to participate in the study. A total of 88 hemodialysis patients were included for the current study, and 56(63.64%) cases were male. The average age of the participating patients was 57 ± 14 years, and 46(52.27%) patients were older than 60 years. 34 (38.64%) cases had diabetes mellitus. Of the participants, 28(31.82%) had cerebrovascular disease (23 had cerebral infarction, 5 had cerebral hemorrhage). The time between the serum klotho measurement and the cerebrovascular disease event was 16.86 ± 8.29 months. In the patients with cerebrovascular disease, 20 (71.43%) cases were male, 15 (53.57%) cases had diabetes mellitus, and 23(82.14%) cases were older than 60 years. The clinical characteristics of participants with cerebrovascular disease were very similar to participants without cerebrovascular disease, except for age and PTH (Table 1). The average level of serum klotho of all participants was 119.10 ± 47.29 pg/ml. As compared to the patients without cerebrovascular disease, serum klotho level was significantly lower in the participants with cerebrovascular disease (91.65 ± 28.19 pg/ml versus 131.90 ± 49.09 pg/ml, P = 0.000) (Table 1).

| Table 1 Characteristics of participants |
|----------------------------------------|
| **With cerebrovascular disease** (n = 28) | **Without cerebrovascular disease** (n = 60) |
| **Total** (n = 88) | **Age, years** | 57 ± 14 | 66 ± 10 | 54 ± 14 ** |
| **Male, n (%)** | 56 (63.64%) | 20 (71.43%) | 36 (60%) |
| **Diabetes history, n (%)** | 34 (38.64%) | 16 (57.14%) | 18 (30%) |
| **Hypertension, n (%)** | 72 (81.82%) | 24 (85.71%) | 48 (80%) |
| **Tobacco smoking, n (%)** | 12 (13.64%) | 4 (14.29%) | 8 (13.33%) |
| **HD vintage (months)** | 34.55 ± 18.57 | 40.86 ± 17.09 | 31.60 ± 18.63 |
| **Klotho (pg/ml)** | 119.10 ± 47.29 | 91.65 ± 28.19 | 131.90 ± 49.09** |
| **Hb (g/L)** | 99.94 ± 15.34 | 100.93 ± 13.12 | 99.48 ± 16.36 |
| **Ca (mmol/L)** | 2.19 ± 0.25 | 2.20 ± 0.23 | 2.18 ± 0.26 |
| **P (mmol/L)** | 1.90 ± 0.52 | 1.84 ± 0.56 | 1.93 ± 0.50 |
| **PTH (pg/ml) a** | 460.23 (185.75–538) | 343.32 (185.75–478.5) | 514.78 (176.50–727.75)* |
| **SF (ng/ml) a** | 410.59 (112–528) | 349.64 (84.5–404.25) | 439.51 (121–582) |
| **Serum iron (umol/L) a** | 10.99 (8.06–13.30) | 10.92 (8.24–12.58) | 11.02 (7.71–13.52) |
| **TIBC (umol/L)** | 47.10 ± 9.16 | 46.95 ± 9.65 | 47.18 ± 9.00 |
| **Tch (mmol/L)** | 3.90 ± 0.99 | 4.05 ± 1.30 | 3.83 ± 0.79 |
| **TG (mmol/L) a** | 1.51 (0.90–1.80) | 1.74 (1.02–1.74) | 1.41 (0.85–1.82) |
| **LDL-C (mmol/L)** | 2.20 ± 0.71 | 2.32 ± 0.91 | 2.14 ± 0.59 |
| **HDL-C (mmol/L)** | 0.96 ± 0.30 | 0.91 ± 0.20 | 0.98 ± 0.34 |
| **ALB (g/L)** | 40.06 ± 3.56 | 39.14 ± 3.13 | 40.44 ± 3.69 |

*Hb* hemoglobin, *Ca* calcium, *P* phosphate, *PTH* parathyroid hormone, *SF* serum ferritin, *TIBC* Total iron binding capacity, *Tch* total cholesterol, *TG* triglycerides, *LDL-C* low-density lipoprotein cholesterol, *HDL-C* high-density lipoprotein cholesterol, *ALB* albumin

*Median (25th–75th percentile). *p < 0.05; **p < 0.01*
Serum klotho and cerebrovascular disease

Cox regression analysis was used to explore the independent risk factors of cerebrovascular disease in hemodialysis patients (Table 2). The results showed that serum klotho (HR(95%CI) = 0.975(0.960–0.990), \( p = 0.001 \)) and age (HR(95%CI) = 1.104(1.038–1.174), \( p = 0.002 \)) were the independent risk factors of cerebrovascular disease in hemodialysis patients.

The ROC curve of klotho relation to cerebrovascular disease is depicted in Fig. 1. The area under the curve (AUC) for klotho and age was 0.728 (95% CI: 0.624–0.831; \( P = 0.001 \)). The optimal cut-off value of serum klotho for predicting cerebrovascular disease was 137.22 pg/ml, with a specificity of 96.4% and a sensitivity of 46.7%.

Correlations between the different parameters and klotho levels

The correlations of serum klotho and different parameters are shown in Table 3. Whether in the crude model or after adjusted for age, serum klotho was not significantly correlation with different parameters of the calcium-phosphate axis, iron metabolism, lipid metabolism, hemoglobin and albumin. But the level of serum klotho was negative correlation with diabetes mellitus (\( r = -0.29, \ p = 0.011 \)).

**Table 2** Cox regression analysis for incident cerebrovascular disease according to baseline variables among 88 hemodialysis patients

|                                | Univariable |          |          |          |          |          |
|--------------------------------|-------------|----------|----------|----------|----------|----------|
|                                | HR(95% CI)  | \( P \)  | HR(95% CI)| \( P \)  | HR(95% CI)| \( P \)  |
| Age, years                     | 1.086 (1.037–1.138) | 0.001**  | 1.104 (1.038–1.174) | 0.001**  |
| Male, n (%)                    | 1.667 (0.632–4.392) | 0.302    |           |           |           |
| Diabetes history, n (%)        | 2.489 (0.927–6.680) | 0.070    |           |           |           |
| Hypertension, n (%)            | 1.500 (0.437–5.148) | 0.519    |           |           |           |
| Tobacco smoking, n (%)         | 1.083 (0.297–3.951) | 0.904    |           |           |           |
| HD vintage (months)            | 1.027 (1.002–1.053) | 0.033*   | 1.027 (0.996–1.058) | 0.086   |
| Klotho (pg/ml)                 | 0.977 (0.965–0.990) | 0.001**  | 0.975 (0.960–0.990) | 0.001**  |
| Hb (g/L)                       | 1.006 (0.977–1.063) | 0.679    |           |           |           |
| Ca (mmol/L)                    | 1.298 (0.217–7.772) | 0.775    |           |           |           |
| P (mmol/L)                     | 0.707 (0.291–1.718) | 0.444    |           |           |           |
| PTH (pg/ml)                    | 0.999 (0.997–1.000) | 0.095    |           |           |           |
| SF (ng/ml)                     | 0.996 (0.909–1.091) | 0.931    |           |           |           |
| Serum iron (umol/L)            | 1.000 (0.998–1.001) | 0.395    |           |           |           |
| TIBC (umol/L)                  | 0.997 (0.949–1.048) | 0.913    |           |           |           |
| Tch (mmol/L)                   | 1.249 (0.794–1.964) | 0.336    |           |           |           |
| TG (mmol/L)                    | 1.448 (0.900–2.330) | 0.127    |           |           |           |
| LDL-C (mmol/L)                 | 1.421 (0.756–2.669) | 0.275    |           |           |           |
| HDL-C (mmol/L)                 | 0.382 (0.073–2.004) | 0.255    |           |           |           |
| ALB (g/L)                      | 0.899 (0.778–1.038) | 0.145    |           |           |           |

\( Hb \) hemoglobin, \( Ca \) calcium, \( P \) phosphate, \( PTH \) parathyroid hormone, \( SF \) serum ferritin, \( TIBC \) Total iron binding capacity, \( Tch \) total cholesterol, \( TG \) triglycerides, \( LDL-C \) low-density lipoprotein cholesterol, \( HDL-C \) high-density lipoprotein cholesterol, \( ALB \) albumin, \( HR \) hazard ratio, 95% CI 95% confidence interval

*\( p < 0.05 \); **\( p < 0.01 \)
Table 3 Correlations between the different parameters and klotho levels

| Parameter | Crude Model | Adjusted for age |
|-----------|-------------|-----------------|
| Ca (mmol/L) | r = -0.121, p = 0.282 | r = 0.012, p = 0.942 |
| P (mmol/L) | r = 0.092, p = 0.422 | r = -0.134, p = 0.272 |
| PTH (pg/ml) | r = 0.000, p = 0.990 | r = 0.140, p = 0.230 |
| Hb (g/L) | r = -0.090, p = 0.370 | r = -0.070, p = 0.570 |
| SF (ng/ml) | r = 0.032, p = 0.810 | r = 0.170, p = 0.172 |
| Serum iron (umol/L) | r = -0.080, p = 0.441 | r = -0.012, p = 0.920 |
| TIBC (umol/L) | r = -0.090, p = 0.401 | r = -0.082, p = 0.491 |
| TG (mmol/L) | r = -0.032, p = 0.782 | r = -0.112, p = 0.351 |
| Tch (mmol/L) | r = -0.041, p = 0.713 | r = -0.092, p = 0.440 |
| LDL-C (mmol/L) | r = 0.031, p = 0.802 | r = -0.042, p = 0.720 |
| HDL-C (mmol/L) | r = -0.011, p = 0.901 | r = -0.022, p = 0.901 |
| ALB (g/L) | r = -0.092, p = 0.461 | r = -0.090, p = 0.430 |
| DM history | r = -0.290, p = 0.011* | r = -2.980, p = 0.013* |
| Hypertension | r = 0.012, p = 0.910 | r = 0.012, p = 0.910 |
| Tobacco smoking | r = 0.110, p = 0.310 | r = 0.123, p = 0.253 |

Ca: calcium, P: phosphate, PTH: parathyroid hormone, Hb: hemoglobin, SF: serum ferritin, TIBC: Total iron binding capacity, TG: triglycerides, Tch: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, ALB: albumin, DM: diabetes mellitus.

and the correlation was remain unchanged after adjusted for age (r = -2.98, p = 0.013).

Serum klotho and cognitive function of patients with cerebrovascular disease

The cognitive function of patients with cerebrovascular disease was assessed with a series of tests. The performance of each cognitive test was shown in Table 4. Compared to the patients with cerebral hemorrhage, the scores of each test in patients with cerebral infarction were not significantly different.

In the crude model, serum klotho was not significantly correlated with the scores of HVLT-R, BVMT-R, VFT and Trail A. But after adjusted for age, the level of serum klotho was significantly correlated with the scores of VFT (r = 0.539, p = 0.021) (Table 5).

Table 4 Cognitive function of cerebrovascular disease, cerebral infarction and cerebral hemorrhage; median (25th–75th percentile)

| Test                  | Cerebrovascular disease n = 28 | Cerebral infarction n = 23 | Cerebral hemorrhage n = 5 |
|-----------------------|--------------------------------|---------------------------|--------------------------|
| MMSE (total score)    | 20.05 (10.00–27.00)            | 17.00 (9.00–27.00)        | 21.00 (17.00–25.00)      |
| HVLT-R (Immediate, words) | 3.00 (1.00–5.00)               | 3.35 (2.00–5.00)         | 1.40 (0.00–3.00)         |
| HVLT-R (Delayed, words) | 2.43 (1.25–4.00)               | 2.48 (1.00–4.00)         | 2.20 (2.00–2.50)         |
| BVMT-R (Immediate, figures) | 1.75 (0.00–3.00)               | 1.87 (0.00–3.00)         | 1.20 (0.00–3.00)         |
| VFT (animal, words)   | 3.79 (2.25–5.00)               | 4.16 (3.00–6.00)         | 2.40 (0.50–4.00)         |
| Trail A (time, s)     | 207.35 (98.25–237.50)          | 186.20 (98.00–190.00)    | 270.80 (159.50–417.50)   |

Table 5 Correlations between the klotho levels and the scores of each cognitive test

| Cognitive Test | Crude Model | Adjusted for age |
|---------------|-------------|-----------------|
| HVLT-R (Immediate recall) | r = 0.210, p = 0.285 | r = 0.426, p = 0.078 |
| HVLT-R (Delayed recall) | r = 0.067, p = 0.735 | r = 0.384, p = 0.116 |
| BVMT-R | r = 0.073, p = 0.711 | r = 0.195, p = 0.439 |
| VFT | r = 0.252, p = 0.235 | r = 0.539, p = 0.021* |
| Trail A | r = -0.720, p = 0.763 | r = -0.084, p = 0.741 |

HVLT-R: Hopkins Verbal Learning Test-Revised, BVMT-R: Brief Visuospatial Memory Test-Revised, VFT: Verbal Fluency Test.

Seventeen cases with cerebral infarction and 5 cases with cerebral hemorrhage had cognitive impairment. Cox regression was used to assess the association between serum klotho and cognitive impairment of dialysis patients with cerebrovascular disease or cerebral infarction (Table 6). In all the patients with cerebrovascular disease or cerebral infarction, klotho was not significantly associated with cognitive impairment, neither in the crude model nor in the models adjusted for age and diabetes.

Discussion

The patients receiving maintain hemodialysis suffer from a serious threat of cerebrovascular disease [2]. It was reported that one-third of hemodialysis patients had experienced stroke symptoms. It means that, in addition to focus on the traditional risk factors for cerebrovascular disease, the exploration of new risk factors in dialysis patients is imminent. To our best knowledge, the current study is the first one to research the relationship between serum klotho level and cerebrovascular disease in hemodialysis patients.

The present study shows that decreased serum klotho concentration is the independently risk factor of cerebrovascular disease. Klotho, as a potential biomarker in renal disease [21], was decreased expression as the CKD progress and contribute to calcium and phosphorus metabolism. Decreased klotho protein expression possibly associated with vascular calcification and endothelial

Table 6 Correlations between the klotho levels and the scores of each cognitive test

| Cognitive Test | Crude Model | Adjusted for age |
|---------------|-------------|-----------------|
| HVLT-R (Immediate recall) | r = 0.210, p = 0.285 | r = 0.426, p = 0.078 |
| HVLT-R (Delayed recall) | r = 0.067, p = 0.735 | r = 0.384, p = 0.116 |
| BVMT-R | r = 0.073, p = 0.711 | r = 0.195, p = 0.439 |
| VFT | r = 0.252, p = 0.235 | r = 0.539, p = 0.021* |
| Trail A | r = -0.720, p = 0.763 | r = -0.084, p = 0.741 |

HVLT-R: Hopkins Verbal Learning Test-Revised, BVMT-R: Brief Visuospatial Memory Test-Revised, VFT: Verbal Fluency Test.

MMSE: mini-mental state examination, HVLT-R: Hopkins Verbal Learning Test-Revised, BVMT-R: Brief Visuospatial Memory Test-Revised, VFT: Verbal Fluency Test.
We found that the level of serum klotho was negatively related with diabetes mellitus after adjusted for age. The previous study also found that serum klotho level was significantly decreased in T2DM patients compared to controls [32]. Further studies confirmed that β-cell-specific expression of klotho was associated with intracellular superoxide levels, oxidative damage, apoptosis, and DNAJC3 (a marker for endoplasmic reticulum stress) [33]. Dyslipidemia was the traditional risk factor for cerebrovascular disease. In the previous studies, plasma klotho was positively correlated with HDL-C [34], and there may have a functional interrelationship between them through insulin signaling, inhibition of apoptosis, or other mechanisms [35]. Metabolic disorders of calcium and phosphorus are common in hemodialysis patients, which always lead to vascular calcification and be closely related with cerebrovascular disease. Buiten MS et al reported that serum klotho was negatively correlated with PTH and Ca in hemodialysis patients [36]. But in the present study, there was no correlation between serum klotho and HDL-C, Ca, P, or PTH in hemodialysis patients. It may because our participants are limited. Whether circulating klotho concentration is associated with lipid, calcium and phosphorus levels in hemodialysis patients needs to be further explored in a large study.

Cognitive impairment is the common sequelae of cerebrovascular disease, especially in hemodialysis patients. In klotho mutant mice at the age of 7 wk., researchers found that long- but not short-term retention of novel object recognition memory is impaired, which was the role of oxidative stress [37]. In Japanese aged 60 or over, there were statistically significant differences in cognitive function for klotho gene promoter polymorphism G-395A. Subjects with the GG type at nucleotide – 395 had lower scores of cognitive function compared to the participants with the GA/AA type [38]. In the present study, serum klotho was correlated with verbal fluency after adjusted for age, but not memory or executive function. Cox regression suggested that serum klotho is not an independent risk factor of cognitive impairment for hemodialysis patients with cerebrovascular disease.

**Strengths and limitations of the study**

The present study is the first to show that serum klotho as a potential predictor of cerebrovascular disease in hemodialysis patients. But only 88 samples is our limitation. Large samples of prospective studies are needed to certify our results. Further studies are needed to explore the reason for the serum klotho decline in hemodialysis patients. Prospective studies will be needed to determine whether treatment of klotho deficiency may be a promising strategy to decrease the burden of comorbidity in hemodialysis patients.

**Conclusions**

The serum klotho level is a potential predictor of cerebrovascular disease in hemodialysis patients, but it is not an independent risk factor of cognitive impairment for hemodialysis patients with cerebrovascular disease.

**Abbreviations**

95% CI: 95% confidence interval; ALB: Albumin; BWT-R: Brief Visuospatial Memory Test-Revised; Ca: Calcium; CKD: Chronic kidney disease; CVD: Cardiovascular disease; DM: Diabetes mellitus; ESRD: End-stage renal disease; Hb: Hemoglobin; HDL-C: High-density lipoprotein cholesterol; HR: Hazard ratio; HVLT-R: Hopkins Verbal Learning Test-Revised; LDL-C: Low-density lipoprotein cholesterol; MMSE: Mini-mental state examination; P: Phosphate; PTH: Parathyroid hormone; SBI: Silent brain infarction; SF: Serum ferritin; Tch: Total cholesterol; TG: Triglycerides; TIBC: Total iron binding capacity; VFT: Verbal Fluency Test

**Acknowledgements**

Not applicable.

**Funding**

This work was supported by Hubei Province Natural Science Fund 2014CFC1047 and Wuhan Health and Family Planning Commission research projects WG15A02, WX18Q31. These funds are responsible for funding support, guiding the research design and supervising the research process.

**Availability of data and materials**

Because the raw data of this article is a part of a big project, so we can't share it temporarily. Two years later, the raw data can be available from the corresponding author on reasonable request.

**Consent to publish**

Not applicable.

**Authors’ contributions**

DJW designed the study and revised the manuscript critically for important intellectual content. WHL and LH made substantial contributions to

| Table 6 | Cox regression analysis the association between klotho and cognitive impairment of hemodialysis patients with cerebrovascular disease or cerebral infarction |
|---------|-------------------------------------------------------------------------------------------------|
|          | Cerebrovascular disease | Cerebral infarction |
|          | HR     | 95% CI     | P     | HR     | 95% CI     | P     |
| Model 1  | 1.003  | 0.988–1.017 | 0.732 | 1.006  | 0.991–1.022 | 0.417 |
| Model 2  | 1.002  | 0.987–1.017 | 0.815 | 1.005  | 0.988–1.021 | 0.589 |
| Model 3  | 1.002  | 0.986–1.018 | 0.776 | 1.005  | 0.987–1.023 | 0.576 |

Model 1, crude model; Model 2, adjusted for age; Model 3, adjusted for age and diabetes.
conception and draft the manuscript. SXH performed the serum klotho levels examination by ELISA. DXG and CY performed CT and MRI scans and collected the results. LCX and DLP evaluated the cognitive function of hemodialysis patients with cerebrovascular disease. All authors read the manuscript, approved the final version and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate
The Biological and Medical Ethics Committee of Puiui Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China) approved the study. All participants have written informed consent before the study.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 5 December 2017 Accepted: 25 January 2019 Published online: 21 February 2019

References
1. Zhang L, Wang F, Wang L, Wang W, Lu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang H, Fu Z, Liu L, Li R, Li M, Wang H, Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–22.
2. Seliger SL, Gillen DL, Longstreth WT Jr, Kestenbaum B, Stehman-Breen CO. Kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study. Am J Kidney Dis. 2009;54(3):468–77.
3. Delmez JA, Yan G, Bailey J, Beck GL, Beddhu S, Cheung AK, Kayser GA, Levey AS, Sarnak MJ, Schwab SJ. Hemodialysis (Hemo) Study Group. Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO study. Am J Kidney Dis. 2006;47(1):131–8.
4. Kurella Tamura M, Meyer JB, Saxena AB, Huh JW, Wadley VG, Schiller B. Prevalence and significance of stroke symptoms among patients receiving maintenance dialysis. Neurology. 2012;79(10):981–7.
5. Abramson JL, Jermakisz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study. Am J Kidney Dis. 2009;54(3):468–77.
6. Toyoda K, Fujii K, Fujimi S, Kumai Y, Tsuchimochi H, Ibayashi S, Iida M. Stroke in patients on maintenance hemodialysis: a 2.2-year single-center study. Am J Kidney Dis. 2005;45(1):1058–66.
7. Imura A, Iwano A, Toyaqocr R, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y. Secreted klotho protein in sera and CSF: implication for post-translational cleavage in release of klotho protein from cell membrane. FEBS Lett. 2004;565(1–3):143–7.
8. Zhang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science. 2005;310(5747):490–3.
9. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lansi K, Razaqzadeh MS, Rosenblatt KP, Baum MG, Kuro-o M, Moe OW. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010;24(9):3438–50.
10. Lindberg K, Olason H, Amin R, Ponnsamy A, Goetz R, Taylor FR, Mohammadi M, Canfield A, Kubickiene K, Larsson TE. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One. 2013;8(4):e60658.
11. Gao MC, Shi M, Zhang J, Quirlones H, Henrik C, Kuro-o M, Moe OW. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011;22(1):124–36.
12. Young GH, Wu VC. KLOTHO methylation is linked to uremic toxins and chronic kidney disease. Kidney Int. 2012;81(7):611–2.
13. Sun CY, Chang SC, Wu MS. Suppression of klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int. 2012;81(7):640–50.
14. Oguro O, Kamide K, Ito N, Nakama K, Kawai T, Takeya Y, Yamamoto K, Sugimoto K, Ikibe K, Gondo Y, Ohishi M, Rakugi H. Klotho gene single nucleotide polymorphism is associated with the onset of stroke, hypertensive organ damages, and plasma klotho protein concentration. Eur Geriatr Med. 2013;4:5101–2.
15. Majumdar V, Nagaraja D, Christopher R. Association of the functional KL-VS variant with early-onset ischemic stroke. Biochem Biophys Res Commun. 2010;403(3):414–2.
16. Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res. 2005;96:412–8.
17. Kim Y, Kim JH, Nam YJ, Kim M, Kim YJ, Yu KH, Lee BC, Lee C. Klotho is a genetic risk factor for ischemic stroke caused by cardioembolism in Korean females. Neurosci Lett. 2006;407:189–94.
18. Majumdar V, Nagaraja D, Christopher R. Is the F352V variant of klotho a risk predictor for stroke in the young? Atherosclerosis. Suppl. 2009;10(2):180.
19. Wu C, Wang Q, Lv C, Qin N, Li S, Yuan Q, Wang G. The changes of serum sKlotho and NGAL levels and their correlation in type 2 diabetes mellitus patients with different stages of urinary albumin. Diabetes Res Clin Pract. 2014;106(2):343–50.
20. Lin Y, Sun Z. In vivo pancreatic β-cell-specific expression of antiaging gene klotho: a novel approach for preserving β-cells in type 2 diabetes. Diabetes. 2015;64(4):1444–58.
21. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C, Guralnik JM, Ferrucci L. Plasma klotho and cardiovascular disease in adults. J Am Geriatr Soc. 2011;59(9):1596–601.
22. Walter M. Interrelationships among HDL metabolism, aging, and atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(12):2440–50.
23. Gonçalves FLC, Elias RM, dos Reis LM, Gracilari FG, Zampieri FG, Oliveira RB, Jorgetti V, Maysés RMA. Soluble klotho is not independently associated with cardiovascular disease in a population of dialysis patients. BMC Nephrol. 2015;16:197.
37. Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, Nabeshima Y, Nabeshima T. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 2003;17(1):50–2.

38. Shimokata H, Ando F, Fukukawa Y, Fukukawa Y, Nishita Y. Klotho gene promoter polymorphism and cognitive impairment. Geriatr Gerontol Int. 2006;6:136–41.